96 related articles for article (PubMed ID: 14710202)
1. Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.
Cappuzzo F; Mazzoni F; Gennari A; Donati S; Salvadori B; Orlandini C; Cetto GL; Molino A; Galligioni E; Mansutti M; Tumolo S; Lucentini A; Valduga F; Bartolini S; Crinò L; Conte PF
Br J Cancer; 2004 Jan; 90(1):31-5. PubMed ID: 14710202
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Conte PF; Gennari A; Donati S; Salvadori B; Baldini E; Bengala C; Pazzagli I; Orlandini C; Danesi R; Fogli S; Del Tacca M
Breast Cancer Res Treat; 2001 Jul; 68(2):171-9. PubMed ID: 11688520
[TBL] [Abstract][Full Text] [Related]
3. Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
Conte PF; Donati S; Gennari A; Guarneri V; Orlandini C; Rondini M; Roncella M; Marini L; Collecchi P; Viacava P; Naccarato AG; Degli Esposti R; Bonardi S; Bottini A; Saracchini S; Tumolo S; Gullo G; Santoro A; Crino L
Br J Cancer; 2005 Aug; 93(4):406-11. PubMed ID: 16052214
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Im SA; Kim SB; Lee MH; Im YH; Lee KH; Song HS; Lee MA; Lee J; Lee NS; Ham HS; Kim TY; Park YH; Lee KE; Kim KW; Seo JH; Lee SN; Hong YS; Bang YJ; Kim WK; Park HS
Oncol Rep; 2005 Aug; 14(2):481-7. PubMed ID: 16012734
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
Zielinski C; Beslija S; Mrsic-Krmpotic Z; Welnicka-Jaskiewicz M; Wiltschke C; Kahan Z; Grgic M; Tzekova V; Inbar M; Cervek J; Chernozemsky I; Szanto J; Spanik S; Wagnerova M; Ghilezan N; Pawlega J; Vrbanec D; Khamtsov D; Soldatenkova V; Brodowicz T
J Clin Oncol; 2005 Mar; 23(7):1401-8. PubMed ID: 15735116
[TBL] [Abstract][Full Text] [Related]
6. The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Gennari A; Donati S; Danesi R; Fogli S; Orlandini C; Del Tacca M; Conte PF
Semin Oncol; 2000 Feb; 27(1 Suppl 2):14-9. PubMed ID: 10697031
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study.
Morales S; Lorenzo A; Ramos M; Ballesteros P; Méndez M; Almanza C; Castellanos J; Moreno-Nogueira JA; Casal J; Lizón J; Oltra A; Frau A; Machengs I; Galán A; Belón J; Llorca C
Cancer Chemother Pharmacol; 2004 Jan; 53(1):75-81. PubMed ID: 14557896
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Passardi A; Massa I; Zoli W; Gianni L; Milandri C; Zumaglini F; Nanni O; Maltoni R; Frassineti GL; Amadori D
BMC Cancer; 2006 Mar; 6():76. PubMed ID: 16551351
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Lück HJ; Du Bois A; Loibl S; Schrader I; Huober J; Heilmann V; Beckmann M; Stähler A; Jackisch C; Hubalek M; Richter B; Stickeler E; Eidtmann H; Thomssen C; Untch M; Wollschläger K; Schuster T; von Minckwitz G
Breast Cancer Res Treat; 2013 Jun; 139(3):779-87. PubMed ID: 23771714
[TBL] [Abstract][Full Text] [Related]
10. The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
Conte P; Salvadori B; Donati S; Gennari A; Cetto GL; Molino A; Crino L; Mazzoni F; Galligioni E; Mansutti M
Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):41-3. PubMed ID: 11252889
[TBL] [Abstract][Full Text] [Related]
11. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
Serin D; Verrill M; Jones A; Delozier T; Coleman R; Kreuser ED; Mross K; Longerey B; Brandely M
Br J Cancer; 2005 Jun; 92(11):1989-96. PubMed ID: 15928659
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA;
Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
Campone M; Fumoleau P; Viens P; Diéras V; Pujade-Lauraine E; Serin D; Petit T; Espié M; Kayitalire L; Bozec L; Pouillart P
Breast; 2006 Oct; 15(5):601-9. PubMed ID: 17045160
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
15. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
[TBL] [Abstract][Full Text] [Related]
16. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01.
Langley RE; Carmichael J; Jones AL; Cameron DA; Qian W; Uscinska B; Howell A; Parmar M
J Clin Oncol; 2005 Nov; 23(33):8322-30. PubMed ID: 16293863
[TBL] [Abstract][Full Text] [Related]
17. Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Viens P; Roché H; Kerbrat P; Fumoleau P; Guastalla JP; Delozier T
Am J Clin Oncol; 2001 Aug; 24(4):328-35. PubMed ID: 11474255
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Venturini M; Durando A; Garrone O; Colozza MA; Contu A; Stevani I; Genta F; Bighin C; Lambiase A; Del Mastro L
Cancer; 2003 Mar; 97(5):1174-80. PubMed ID: 12599222
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Hamm JT; Wilson JW; Rastogi P; Lembersky BC; Tseng GC; Song YK; Kim W; Robidoux A; Raymond JM; Kardinal CG; Shalaby IA; Ansari R; Paik S; Geyer CE; Wolmark N;
Clin Breast Cancer; 2008 Jun; 8(3):257-63. PubMed ID: 18650156
[TBL] [Abstract][Full Text] [Related]
20. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer.
Bonneterre J; Dieras V; Tubiana-Hulin M; Bougnoux P; Bonneterre ME; Delozier T; Mayer F; Culine S; Dohoulou N; Bendahmane B
Br J Cancer; 2004 Oct; 91(8):1466-71. PubMed ID: 15381937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
